论文部分内容阅读
目的:观察玻璃体腔注射bevacizumab(Avastin)治疗视网膜分支静脉阻塞性黄斑水肿的有效性和安全性。方法:观察一组视网膜分支静脉阻塞引起黄斑水肿的连续病例,对其进行玻璃体腔注射bevacizumab(Avastin)后的疗效进行分析。所有患者在治疗开始前以及治疗后随诊时间点均进行完全的眼科相关检查,包括视力测定,OCT和/或FFA检查。结果:对32例患者(32眼)分别至少进行一次玻璃体腔注药(1～3次),术后平均观察时间为4.7mo。平均视力:治疗前为20/200-,治疗后1mo20/100-,治疗后3mo及最近一次检查为20/100+(P<0.01);黄斑中心1mm区厚度:治疗前为483μm,治疗后1,3mo及最近一次分别为275,314和301μm(P<0.01)。没有观察到任何不良副作用。结论:玻璃体腔注射bvacizumab(Avastin)治疗能显著减轻视网膜分支静脉阻塞性黄斑水肿、提高视力且没有不良反应。
Objective: To observe the efficacy and safety of intravitreal injection of bevacizumab (Avastin) in the treatment of retinal vein occlusive macular edema. Methods: A series of continuous cases of macular edema caused by occlusion of retinal branch vein were observed. The efficacy of intravitreal injection of bevacizumab (Avastin) was analyzed. All patients underwent complete ophthalmic-related examinations, including visual acuity, OCT, and / or FFA, before beginning treatment and at the time points following treatment. Results: 32 patients (32 eyes) were injected with vitreous cavity at least once (1-3 times) respectively. The average postoperative observation time was 4.7 months. The average visual acuity was 20 / 200- before treatment, 1mo20 / 100- after treatment, 3mo after treatment and 20/100 + for the most recent examination (P <0.01). The thickness of 1mm area in macular center was 483μm before treatment, , 3mo and most recently 275, 314 and 301μm respectively (P <0.01). No adverse side effects were observed. Conclusion: Intravitreal injection of bvacizumab (Avastin) can significantly reduce retinal vein occlusive macular edema, improve visual acuity and no adverse reactions.